Pharma & Healthcare
Global Monoclonal Antibodies for Non-small Cell Lung Cancer Market Research Report 2025
- Jan 17, 26
- ID: 18484
- Pages: 96
- Figures: 89
- Views: 58
Report Scope
This report aims to provide a comprehensive presentation of the global market for Monoclonal Antibodies for Non-small Cell Lung Cancer, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Monoclonal Antibodies for Non-small Cell Lung Cancer.
The Monoclonal Antibodies for Non-small Cell Lung Cancer market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Monoclonal Antibodies for Non-small Cell Lung Cancer market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Monoclonal Antibodies for Non-small Cell Lung Cancer manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
By Company
Roche Holding AG
Bristol Myers Squibb Co.
Elea Spa
Eli Lilly & Co.
Merck & Co., Inc.
AstraZeneca PLC
Regeneron Pharmaceuticals, Inc.
Henlius Biopharma Co., Ltd
Jiangsu Hengrui Medicine Co., Ltd
Innovent Biologics Co., Ltd
Junshi Biosciences Co., Ltd
BeiGene, Ltd
Akeso, Inc
Segment by Type
5 mg/mL
10 mg/mL
25 mg/mL
50 mg/mL
Segment by Application
Hospitals
Clinic
Others
Consumption by Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
Europe
Germany
France
U.K.
Italy
Russia
Latin America
Mexico
Brazil
Argentina
Colombia
Middle East and Africa
Turkey
Saudi Arabia
UAE
Core Chapters
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Monoclonal Antibodies for Non-small Cell Lung Cancer manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Monoclonal Antibodies for Non-small Cell Lung Cancer in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
This report aims to provide a comprehensive presentation of the global market for Monoclonal Antibodies for Non-small Cell Lung Cancer, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Monoclonal Antibodies for Non-small Cell Lung Cancer.
The Monoclonal Antibodies for Non-small Cell Lung Cancer market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Monoclonal Antibodies for Non-small Cell Lung Cancer market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Monoclonal Antibodies for Non-small Cell Lung Cancer manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
By Company
Roche Holding AG
Bristol Myers Squibb Co.
Elea Spa
Eli Lilly & Co.
Merck & Co., Inc.
AstraZeneca PLC
Regeneron Pharmaceuticals, Inc.
Henlius Biopharma Co., Ltd
Jiangsu Hengrui Medicine Co., Ltd
Innovent Biologics Co., Ltd
Junshi Biosciences Co., Ltd
BeiGene, Ltd
Akeso, Inc
Segment by Type
5 mg/mL
10 mg/mL
25 mg/mL
50 mg/mL
Segment by Application
Hospitals
Clinic
Others
Consumption by Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
Europe
Germany
France
U.K.
Italy
Russia
Latin America
Mexico
Brazil
Argentina
Colombia
Middle East and Africa
Turkey
Saudi Arabia
UAE
Core Chapters
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Monoclonal Antibodies for Non-small Cell Lung Cancer manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Monoclonal Antibodies for Non-small Cell Lung Cancer in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
1 Monoclonal Antibodies for Non-small Cell Lung Cancer Market Overview
1.1 Product Definition
1.2 Monoclonal Antibodies for Non-small Cell Lung Cancer by Type
1.2.1 Global Monoclonal Antibodies for Non-small Cell Lung Cancer Market Value Comparison by Type (2024 VS 2031)
1.2.2 5 mg/mL
1.2.3 10 mg/mL
1.2.4 25 mg/mL
1.2.5 50 mg/mL
1.3 Monoclonal Antibodies for Non-small Cell Lung Cancer by Application
1.3.1 Global Monoclonal Antibodies for Non-small Cell Lung Cancer Market Value by Application (2024 VS 2031)
1.3.2 Hospitals
1.3.3 Clinic
1.3.4 Others
1.4 Global Monoclonal Antibodies for Non-small Cell Lung Cancer Market Size Estimates and Forecasts
1.4.1 Global Monoclonal Antibodies for Non-small Cell Lung Cancer Revenue 2020-2031
1.4.2 Global Monoclonal Antibodies for Non-small Cell Lung Cancer Sales 2020-2031
1.4.3 Global Monoclonal Antibodies for Non-small Cell Lung Cancer Market Average Price (2020-2031)
1.5 Assumptions and Limitations
2 Monoclonal Antibodies for Non-small Cell Lung Cancer Market Competition by Manufacturers
2.1 Global Monoclonal Antibodies for Non-small Cell Lung Cancer Sales Market Share by Manufacturers (2020-2025)
2.2 Global Monoclonal Antibodies for Non-small Cell Lung Cancer Revenue Market Share by Manufacturers (2020-2025)
2.3 Global Monoclonal Antibodies for Non-small Cell Lung Cancer Average Price by Manufacturers (2020-2025)
2.4 Global Key Players of Monoclonal Antibodies for Non-small Cell Lung Cancer, Industry Ranking, 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Monoclonal Antibodies for Non-small Cell Lung Cancer, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Monoclonal Antibodies for Non-small Cell Lung Cancer, Product Type & Application
2.7 Global Key Manufacturers of Monoclonal Antibodies for Non-small Cell Lung Cancer, Date of Enter into This Industry
2.8 Global Monoclonal Antibodies for Non-small Cell Lung Cancer Market Competitive Situation and Trends
2.8.1 Global Monoclonal Antibodies for Non-small Cell Lung Cancer Market Concentration Rate
2.8.2 The Global 5 and 10 Largest Monoclonal Antibodies for Non-small Cell Lung Cancer Players Market Share by Revenue
2.8.3 Global Monoclonal Antibodies for Non-small Cell Lung Cancer Company Type and Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
2.9 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Global Monoclonal Antibodies for Non-small Cell Lung Cancer Market Scenario by Region
3.1 Global Monoclonal Antibodies for Non-small Cell Lung Cancer Market Size by Region: 2020 Versus 2024 Versus 2031
3.2 Global Monoclonal Antibodies for Non-small Cell Lung Cancer Sales by Region: 2020-2031
3.2.1 Global Monoclonal Antibodies for Non-small Cell Lung Cancer Sales by Region: 2020-2025
3.2.2 Global Monoclonal Antibodies for Non-small Cell Lung Cancer Sales by Region: 2026-2031
3.3 Global Monoclonal Antibodies for Non-small Cell Lung Cancer Revenue by Region: 2020-2031
3.3.1 Global Monoclonal Antibodies for Non-small Cell Lung Cancer Revenue by Region: 2020-2025
3.3.2 Global Monoclonal Antibodies for Non-small Cell Lung Cancer Revenue by Region: 2026-2031
3.4 North America Monoclonal Antibodies for Non-small Cell Lung Cancer Market Facts & Figures by Country
3.4.1 North America Monoclonal Antibodies for Non-small Cell Lung Cancer Market Size by Country: 2020 VS 2024 VS 2031
3.4.2 North America Monoclonal Antibodies for Non-small Cell Lung Cancer Sales by Country (2020-2031)
3.4.3 North America Monoclonal Antibodies for Non-small Cell Lung Cancer Revenue by Country (2020-2031)
3.4.4 United States
3.4.5 Canada
3.5 Europe Monoclonal Antibodies for Non-small Cell Lung Cancer Market Facts & Figures by Country
3.5.1 Europe Monoclonal Antibodies for Non-small Cell Lung Cancer Market Size by Country: 2020 VS 2024 VS 2031
3.5.2 Europe Monoclonal Antibodies for Non-small Cell Lung Cancer Sales by Country (2020-2031)
3.5.3 Europe Monoclonal Antibodies for Non-small Cell Lung Cancer Revenue by Country (2020-2031)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Monoclonal Antibodies for Non-small Cell Lung Cancer Market Facts & Figures by Region
3.6.1 Asia Pacific Monoclonal Antibodies for Non-small Cell Lung Cancer Market Size by Region: 2020 VS 2024 VS 2031
3.6.2 Asia Pacific Monoclonal Antibodies for Non-small Cell Lung Cancer Sales by Region (2020-2031)
3.6.3 Asia Pacific Monoclonal Antibodies for Non-small Cell Lung Cancer Revenue by Region (2020-2031)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Southeast Asia
3.7 Latin America Monoclonal Antibodies for Non-small Cell Lung Cancer Market Facts & Figures by Country
3.7.1 Latin America Monoclonal Antibodies for Non-small Cell Lung Cancer Market Size by Country: 2020 VS 2024 VS 2031
3.7.2 Latin America Monoclonal Antibodies for Non-small Cell Lung Cancer Sales by Country (2020-2031)
3.7.3 Latin America Monoclonal Antibodies for Non-small Cell Lung Cancer Revenue by Country (2020-2031)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.7.7 Colombia
3.8 Middle East and Africa Monoclonal Antibodies for Non-small Cell Lung Cancer Market Facts & Figures by Country
3.8.1 Middle East and Africa Monoclonal Antibodies for Non-small Cell Lung Cancer Market Size by Country: 2020 VS 2024 VS 2031
3.8.2 Middle East and Africa Monoclonal Antibodies for Non-small Cell Lung Cancer Sales by Country (2020-2031)
3.8.3 Middle East and Africa Monoclonal Antibodies for Non-small Cell Lung Cancer Revenue by Country (2020-2031)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Monoclonal Antibodies for Non-small Cell Lung Cancer Sales by Type (2020-2031)
4.1.1 Global Monoclonal Antibodies for Non-small Cell Lung Cancer Sales by Type (2020-2025)
4.1.2 Global Monoclonal Antibodies for Non-small Cell Lung Cancer Sales by Type (2026-2031)
4.1.3 Global Monoclonal Antibodies for Non-small Cell Lung Cancer Sales Market Share by Type (2020-2031)
4.2 Global Monoclonal Antibodies for Non-small Cell Lung Cancer Revenue by Type (2020-2031)
4.2.1 Global Monoclonal Antibodies for Non-small Cell Lung Cancer Revenue by Type (2020-2025)
4.2.2 Global Monoclonal Antibodies for Non-small Cell Lung Cancer Revenue by Type (2026-2031)
4.2.3 Global Monoclonal Antibodies for Non-small Cell Lung Cancer Revenue Market Share by Type (2020-2031)
4.3 Global Monoclonal Antibodies for Non-small Cell Lung Cancer Price by Type (2020-2031)
5 Segment by Application
5.1 Global Monoclonal Antibodies for Non-small Cell Lung Cancer Sales by Application (2020-2031)
5.1.1 Global Monoclonal Antibodies for Non-small Cell Lung Cancer Sales by Application (2020-2025)
5.1.2 Global Monoclonal Antibodies for Non-small Cell Lung Cancer Sales by Application (2026-2031)
5.1.3 Global Monoclonal Antibodies for Non-small Cell Lung Cancer Sales Market Share by Application (2020-2031)
5.2 Global Monoclonal Antibodies for Non-small Cell Lung Cancer Revenue by Application (2020-2031)
5.2.1 Global Monoclonal Antibodies for Non-small Cell Lung Cancer Revenue by Application (2020-2025)
5.2.2 Global Monoclonal Antibodies for Non-small Cell Lung Cancer Revenue by Application (2026-2031)
5.2.3 Global Monoclonal Antibodies for Non-small Cell Lung Cancer Revenue Market Share by Application (2020-2031)
5.3 Global Monoclonal Antibodies for Non-small Cell Lung Cancer Price by Application (2020-2031)
6 Key Companies Profiled
6.1 Roche Holding AG
6.1.1 Roche Holding AG Company Information
6.1.2 Roche Holding AG Description and Business Overview
6.1.3 Roche Holding AG Monoclonal Antibodies for Non-small Cell Lung Cancer Sales, Revenue and Gross Margin (2020-2025)
6.1.4 Roche Holding AG Monoclonal Antibodies for Non-small Cell Lung Cancer Product Portfolio
6.1.5 Roche Holding AG Recent Developments/Updates
6.2 Bristol Myers Squibb Co.
6.2.1 Bristol Myers Squibb Co. Company Information
6.2.2 Bristol Myers Squibb Co. Description and Business Overview
6.2.3 Bristol Myers Squibb Co. Monoclonal Antibodies for Non-small Cell Lung Cancer Sales, Revenue and Gross Margin (2020-2025)
6.2.4 Bristol Myers Squibb Co. Monoclonal Antibodies for Non-small Cell Lung Cancer Product Portfolio
6.2.5 Bristol Myers Squibb Co. Recent Developments/Updates
6.3 Elea Spa
6.3.1 Elea Spa Company Information
6.3.2 Elea Spa Description and Business Overview
6.3.3 Elea Spa Monoclonal Antibodies for Non-small Cell Lung Cancer Sales, Revenue and Gross Margin (2020-2025)
6.3.4 Elea Spa Monoclonal Antibodies for Non-small Cell Lung Cancer Product Portfolio
6.3.5 Elea Spa Recent Developments/Updates
6.4 Eli Lilly & Co.
6.4.1 Eli Lilly & Co. Company Information
6.4.2 Eli Lilly & Co. Description and Business Overview
6.4.3 Eli Lilly & Co. Monoclonal Antibodies for Non-small Cell Lung Cancer Sales, Revenue and Gross Margin (2020-2025)
6.4.4 Eli Lilly & Co. Monoclonal Antibodies for Non-small Cell Lung Cancer Product Portfolio
6.4.5 Eli Lilly & Co. Recent Developments/Updates
6.5 Merck & Co., Inc.
6.5.1 Merck & Co., Inc. Company Information
6.5.2 Merck & Co., Inc. Description and Business Overview
6.5.3 Merck & Co., Inc. Monoclonal Antibodies for Non-small Cell Lung Cancer Sales, Revenue and Gross Margin (2020-2025)
6.5.4 Merck & Co., Inc. Monoclonal Antibodies for Non-small Cell Lung Cancer Product Portfolio
6.5.5 Merck & Co., Inc. Recent Developments/Updates
6.6 AstraZeneca PLC
6.6.1 AstraZeneca PLC Company Information
6.6.2 AstraZeneca PLC Description and Business Overview
6.6.3 AstraZeneca PLC Monoclonal Antibodies for Non-small Cell Lung Cancer Sales, Revenue and Gross Margin (2020-2025)
6.6.4 AstraZeneca PLC Monoclonal Antibodies for Non-small Cell Lung Cancer Product Portfolio
6.6.5 AstraZeneca PLC Recent Developments/Updates
6.7 Regeneron Pharmaceuticals, Inc.
6.7.1 Regeneron Pharmaceuticals, Inc. Company Information
6.7.2 Regeneron Pharmaceuticals, Inc. Description and Business Overview
6.7.3 Regeneron Pharmaceuticals, Inc. Monoclonal Antibodies for Non-small Cell Lung Cancer Sales, Revenue and Gross Margin (2020-2025)
6.7.4 Regeneron Pharmaceuticals, Inc. Monoclonal Antibodies for Non-small Cell Lung Cancer Product Portfolio
6.7.5 Regeneron Pharmaceuticals, Inc. Recent Developments/Updates
6.8 Henlius Biopharma Co., Ltd
6.8.1 Henlius Biopharma Co., Ltd Company Information
6.8.2 Henlius Biopharma Co., Ltd Description and Business Overview
6.8.3 Henlius Biopharma Co., Ltd Monoclonal Antibodies for Non-small Cell Lung Cancer Sales, Revenue and Gross Margin (2020-2025)
6.8.4 Henlius Biopharma Co., Ltd Monoclonal Antibodies for Non-small Cell Lung Cancer Product Portfolio
6.8.5 Henlius Biopharma Co., Ltd Recent Developments/Updates
6.9 Jiangsu Hengrui Medicine Co., Ltd
6.9.1 Jiangsu Hengrui Medicine Co., Ltd Company Information
6.9.2 Jiangsu Hengrui Medicine Co., Ltd Description and Business Overview
6.9.3 Jiangsu Hengrui Medicine Co., Ltd Monoclonal Antibodies for Non-small Cell Lung Cancer Sales, Revenue and Gross Margin (2020-2025)
6.9.4 Jiangsu Hengrui Medicine Co., Ltd Monoclonal Antibodies for Non-small Cell Lung Cancer Product Portfolio
6.9.5 Jiangsu Hengrui Medicine Co., Ltd Recent Developments/Updates
6.10 Innovent Biologics Co., Ltd
6.10.1 Innovent Biologics Co., Ltd Company Information
6.10.2 Innovent Biologics Co., Ltd Description and Business Overview
6.10.3 Innovent Biologics Co., Ltd Monoclonal Antibodies for Non-small Cell Lung Cancer Sales, Revenue and Gross Margin (2020-2025)
6.10.4 Innovent Biologics Co., Ltd Monoclonal Antibodies for Non-small Cell Lung Cancer Product Portfolio
6.10.5 Innovent Biologics Co., Ltd Recent Developments/Updates
6.11 Junshi Biosciences Co., Ltd
6.11.1 Junshi Biosciences Co., Ltd Company Information
6.11.2 Junshi Biosciences Co., Ltd Description and Business Overview
6.11.3 Junshi Biosciences Co., Ltd Monoclonal Antibodies for Non-small Cell Lung Cancer Sales, Revenue and Gross Margin (2020-2025)
6.11.4 Junshi Biosciences Co., Ltd Monoclonal Antibodies for Non-small Cell Lung Cancer Product Portfolio
6.11.5 Junshi Biosciences Co., Ltd Recent Developments/Updates
6.12 BeiGene, Ltd
6.12.1 BeiGene, Ltd Company Information
6.12.2 BeiGene, Ltd Description and Business Overview
6.12.3 BeiGene, Ltd Monoclonal Antibodies for Non-small Cell Lung Cancer Sales, Revenue and Gross Margin (2020-2025)
6.12.4 BeiGene, Ltd Monoclonal Antibodies for Non-small Cell Lung Cancer Product Portfolio
6.12.5 BeiGene, Ltd Recent Developments/Updates
6.13 Akeso, Inc
6.13.1 Akeso, Inc Company Information
6.13.2 Akeso, Inc Description and Business Overview
6.13.3 Akeso, Inc Monoclonal Antibodies for Non-small Cell Lung Cancer Sales, Revenue and Gross Margin (2020-2025)
6.13.4 Akeso, Inc Monoclonal Antibodies for Non-small Cell Lung Cancer Product Portfolio
6.13.5 Akeso, Inc Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Monoclonal Antibodies for Non-small Cell Lung Cancer Industry Chain Analysis
7.2 Monoclonal Antibodies for Non-small Cell Lung Cancer Raw Material Supply Analysis
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Monoclonal Antibodies for Non-small Cell Lung Cancer Production Mode & Process Analysis
7.4 Monoclonal Antibodies for Non-small Cell Lung Cancer Sales and Marketing
7.4.1 Monoclonal Antibodies for Non-small Cell Lung Cancer Sales Channels
7.4.2 Monoclonal Antibodies for Non-small Cell Lung Cancer Distributors
7.5 Monoclonal Antibodies for Non-small Cell Lung Cancer Customer Analysis
8 Monoclonal Antibodies for Non-small Cell Lung Cancer Market Dynamics
8.1 Monoclonal Antibodies for Non-small Cell Lung Cancer Industry Trends
8.2 Monoclonal Antibodies for Non-small Cell Lung Cancer Market Drivers
8.3 Monoclonal Antibodies for Non-small Cell Lung Cancer Market Challenges
8.4 Monoclonal Antibodies for Non-small Cell Lung Cancer Market Restraints
9 Research Findings and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
1.1 Product Definition
1.2 Monoclonal Antibodies for Non-small Cell Lung Cancer by Type
1.2.1 Global Monoclonal Antibodies for Non-small Cell Lung Cancer Market Value Comparison by Type (2024 VS 2031)
1.2.2 5 mg/mL
1.2.3 10 mg/mL
1.2.4 25 mg/mL
1.2.5 50 mg/mL
1.3 Monoclonal Antibodies for Non-small Cell Lung Cancer by Application
1.3.1 Global Monoclonal Antibodies for Non-small Cell Lung Cancer Market Value by Application (2024 VS 2031)
1.3.2 Hospitals
1.3.3 Clinic
1.3.4 Others
1.4 Global Monoclonal Antibodies for Non-small Cell Lung Cancer Market Size Estimates and Forecasts
1.4.1 Global Monoclonal Antibodies for Non-small Cell Lung Cancer Revenue 2020-2031
1.4.2 Global Monoclonal Antibodies for Non-small Cell Lung Cancer Sales 2020-2031
1.4.3 Global Monoclonal Antibodies for Non-small Cell Lung Cancer Market Average Price (2020-2031)
1.5 Assumptions and Limitations
2 Monoclonal Antibodies for Non-small Cell Lung Cancer Market Competition by Manufacturers
2.1 Global Monoclonal Antibodies for Non-small Cell Lung Cancer Sales Market Share by Manufacturers (2020-2025)
2.2 Global Monoclonal Antibodies for Non-small Cell Lung Cancer Revenue Market Share by Manufacturers (2020-2025)
2.3 Global Monoclonal Antibodies for Non-small Cell Lung Cancer Average Price by Manufacturers (2020-2025)
2.4 Global Key Players of Monoclonal Antibodies for Non-small Cell Lung Cancer, Industry Ranking, 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Monoclonal Antibodies for Non-small Cell Lung Cancer, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Monoclonal Antibodies for Non-small Cell Lung Cancer, Product Type & Application
2.7 Global Key Manufacturers of Monoclonal Antibodies for Non-small Cell Lung Cancer, Date of Enter into This Industry
2.8 Global Monoclonal Antibodies for Non-small Cell Lung Cancer Market Competitive Situation and Trends
2.8.1 Global Monoclonal Antibodies for Non-small Cell Lung Cancer Market Concentration Rate
2.8.2 The Global 5 and 10 Largest Monoclonal Antibodies for Non-small Cell Lung Cancer Players Market Share by Revenue
2.8.3 Global Monoclonal Antibodies for Non-small Cell Lung Cancer Company Type and Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
2.9 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Global Monoclonal Antibodies for Non-small Cell Lung Cancer Market Scenario by Region
3.1 Global Monoclonal Antibodies for Non-small Cell Lung Cancer Market Size by Region: 2020 Versus 2024 Versus 2031
3.2 Global Monoclonal Antibodies for Non-small Cell Lung Cancer Sales by Region: 2020-2031
3.2.1 Global Monoclonal Antibodies for Non-small Cell Lung Cancer Sales by Region: 2020-2025
3.2.2 Global Monoclonal Antibodies for Non-small Cell Lung Cancer Sales by Region: 2026-2031
3.3 Global Monoclonal Antibodies for Non-small Cell Lung Cancer Revenue by Region: 2020-2031
3.3.1 Global Monoclonal Antibodies for Non-small Cell Lung Cancer Revenue by Region: 2020-2025
3.3.2 Global Monoclonal Antibodies for Non-small Cell Lung Cancer Revenue by Region: 2026-2031
3.4 North America Monoclonal Antibodies for Non-small Cell Lung Cancer Market Facts & Figures by Country
3.4.1 North America Monoclonal Antibodies for Non-small Cell Lung Cancer Market Size by Country: 2020 VS 2024 VS 2031
3.4.2 North America Monoclonal Antibodies for Non-small Cell Lung Cancer Sales by Country (2020-2031)
3.4.3 North America Monoclonal Antibodies for Non-small Cell Lung Cancer Revenue by Country (2020-2031)
3.4.4 United States
3.4.5 Canada
3.5 Europe Monoclonal Antibodies for Non-small Cell Lung Cancer Market Facts & Figures by Country
3.5.1 Europe Monoclonal Antibodies for Non-small Cell Lung Cancer Market Size by Country: 2020 VS 2024 VS 2031
3.5.2 Europe Monoclonal Antibodies for Non-small Cell Lung Cancer Sales by Country (2020-2031)
3.5.3 Europe Monoclonal Antibodies for Non-small Cell Lung Cancer Revenue by Country (2020-2031)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Monoclonal Antibodies for Non-small Cell Lung Cancer Market Facts & Figures by Region
3.6.1 Asia Pacific Monoclonal Antibodies for Non-small Cell Lung Cancer Market Size by Region: 2020 VS 2024 VS 2031
3.6.2 Asia Pacific Monoclonal Antibodies for Non-small Cell Lung Cancer Sales by Region (2020-2031)
3.6.3 Asia Pacific Monoclonal Antibodies for Non-small Cell Lung Cancer Revenue by Region (2020-2031)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Southeast Asia
3.7 Latin America Monoclonal Antibodies for Non-small Cell Lung Cancer Market Facts & Figures by Country
3.7.1 Latin America Monoclonal Antibodies for Non-small Cell Lung Cancer Market Size by Country: 2020 VS 2024 VS 2031
3.7.2 Latin America Monoclonal Antibodies for Non-small Cell Lung Cancer Sales by Country (2020-2031)
3.7.3 Latin America Monoclonal Antibodies for Non-small Cell Lung Cancer Revenue by Country (2020-2031)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.7.7 Colombia
3.8 Middle East and Africa Monoclonal Antibodies for Non-small Cell Lung Cancer Market Facts & Figures by Country
3.8.1 Middle East and Africa Monoclonal Antibodies for Non-small Cell Lung Cancer Market Size by Country: 2020 VS 2024 VS 2031
3.8.2 Middle East and Africa Monoclonal Antibodies for Non-small Cell Lung Cancer Sales by Country (2020-2031)
3.8.3 Middle East and Africa Monoclonal Antibodies for Non-small Cell Lung Cancer Revenue by Country (2020-2031)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Monoclonal Antibodies for Non-small Cell Lung Cancer Sales by Type (2020-2031)
4.1.1 Global Monoclonal Antibodies for Non-small Cell Lung Cancer Sales by Type (2020-2025)
4.1.2 Global Monoclonal Antibodies for Non-small Cell Lung Cancer Sales by Type (2026-2031)
4.1.3 Global Monoclonal Antibodies for Non-small Cell Lung Cancer Sales Market Share by Type (2020-2031)
4.2 Global Monoclonal Antibodies for Non-small Cell Lung Cancer Revenue by Type (2020-2031)
4.2.1 Global Monoclonal Antibodies for Non-small Cell Lung Cancer Revenue by Type (2020-2025)
4.2.2 Global Monoclonal Antibodies for Non-small Cell Lung Cancer Revenue by Type (2026-2031)
4.2.3 Global Monoclonal Antibodies for Non-small Cell Lung Cancer Revenue Market Share by Type (2020-2031)
4.3 Global Monoclonal Antibodies for Non-small Cell Lung Cancer Price by Type (2020-2031)
5 Segment by Application
5.1 Global Monoclonal Antibodies for Non-small Cell Lung Cancer Sales by Application (2020-2031)
5.1.1 Global Monoclonal Antibodies for Non-small Cell Lung Cancer Sales by Application (2020-2025)
5.1.2 Global Monoclonal Antibodies for Non-small Cell Lung Cancer Sales by Application (2026-2031)
5.1.3 Global Monoclonal Antibodies for Non-small Cell Lung Cancer Sales Market Share by Application (2020-2031)
5.2 Global Monoclonal Antibodies for Non-small Cell Lung Cancer Revenue by Application (2020-2031)
5.2.1 Global Monoclonal Antibodies for Non-small Cell Lung Cancer Revenue by Application (2020-2025)
5.2.2 Global Monoclonal Antibodies for Non-small Cell Lung Cancer Revenue by Application (2026-2031)
5.2.3 Global Monoclonal Antibodies for Non-small Cell Lung Cancer Revenue Market Share by Application (2020-2031)
5.3 Global Monoclonal Antibodies for Non-small Cell Lung Cancer Price by Application (2020-2031)
6 Key Companies Profiled
6.1 Roche Holding AG
6.1.1 Roche Holding AG Company Information
6.1.2 Roche Holding AG Description and Business Overview
6.1.3 Roche Holding AG Monoclonal Antibodies for Non-small Cell Lung Cancer Sales, Revenue and Gross Margin (2020-2025)
6.1.4 Roche Holding AG Monoclonal Antibodies for Non-small Cell Lung Cancer Product Portfolio
6.1.5 Roche Holding AG Recent Developments/Updates
6.2 Bristol Myers Squibb Co.
6.2.1 Bristol Myers Squibb Co. Company Information
6.2.2 Bristol Myers Squibb Co. Description and Business Overview
6.2.3 Bristol Myers Squibb Co. Monoclonal Antibodies for Non-small Cell Lung Cancer Sales, Revenue and Gross Margin (2020-2025)
6.2.4 Bristol Myers Squibb Co. Monoclonal Antibodies for Non-small Cell Lung Cancer Product Portfolio
6.2.5 Bristol Myers Squibb Co. Recent Developments/Updates
6.3 Elea Spa
6.3.1 Elea Spa Company Information
6.3.2 Elea Spa Description and Business Overview
6.3.3 Elea Spa Monoclonal Antibodies for Non-small Cell Lung Cancer Sales, Revenue and Gross Margin (2020-2025)
6.3.4 Elea Spa Monoclonal Antibodies for Non-small Cell Lung Cancer Product Portfolio
6.3.5 Elea Spa Recent Developments/Updates
6.4 Eli Lilly & Co.
6.4.1 Eli Lilly & Co. Company Information
6.4.2 Eli Lilly & Co. Description and Business Overview
6.4.3 Eli Lilly & Co. Monoclonal Antibodies for Non-small Cell Lung Cancer Sales, Revenue and Gross Margin (2020-2025)
6.4.4 Eli Lilly & Co. Monoclonal Antibodies for Non-small Cell Lung Cancer Product Portfolio
6.4.5 Eli Lilly & Co. Recent Developments/Updates
6.5 Merck & Co., Inc.
6.5.1 Merck & Co., Inc. Company Information
6.5.2 Merck & Co., Inc. Description and Business Overview
6.5.3 Merck & Co., Inc. Monoclonal Antibodies for Non-small Cell Lung Cancer Sales, Revenue and Gross Margin (2020-2025)
6.5.4 Merck & Co., Inc. Monoclonal Antibodies for Non-small Cell Lung Cancer Product Portfolio
6.5.5 Merck & Co., Inc. Recent Developments/Updates
6.6 AstraZeneca PLC
6.6.1 AstraZeneca PLC Company Information
6.6.2 AstraZeneca PLC Description and Business Overview
6.6.3 AstraZeneca PLC Monoclonal Antibodies for Non-small Cell Lung Cancer Sales, Revenue and Gross Margin (2020-2025)
6.6.4 AstraZeneca PLC Monoclonal Antibodies for Non-small Cell Lung Cancer Product Portfolio
6.6.5 AstraZeneca PLC Recent Developments/Updates
6.7 Regeneron Pharmaceuticals, Inc.
6.7.1 Regeneron Pharmaceuticals, Inc. Company Information
6.7.2 Regeneron Pharmaceuticals, Inc. Description and Business Overview
6.7.3 Regeneron Pharmaceuticals, Inc. Monoclonal Antibodies for Non-small Cell Lung Cancer Sales, Revenue and Gross Margin (2020-2025)
6.7.4 Regeneron Pharmaceuticals, Inc. Monoclonal Antibodies for Non-small Cell Lung Cancer Product Portfolio
6.7.5 Regeneron Pharmaceuticals, Inc. Recent Developments/Updates
6.8 Henlius Biopharma Co., Ltd
6.8.1 Henlius Biopharma Co., Ltd Company Information
6.8.2 Henlius Biopharma Co., Ltd Description and Business Overview
6.8.3 Henlius Biopharma Co., Ltd Monoclonal Antibodies for Non-small Cell Lung Cancer Sales, Revenue and Gross Margin (2020-2025)
6.8.4 Henlius Biopharma Co., Ltd Monoclonal Antibodies for Non-small Cell Lung Cancer Product Portfolio
6.8.5 Henlius Biopharma Co., Ltd Recent Developments/Updates
6.9 Jiangsu Hengrui Medicine Co., Ltd
6.9.1 Jiangsu Hengrui Medicine Co., Ltd Company Information
6.9.2 Jiangsu Hengrui Medicine Co., Ltd Description and Business Overview
6.9.3 Jiangsu Hengrui Medicine Co., Ltd Monoclonal Antibodies for Non-small Cell Lung Cancer Sales, Revenue and Gross Margin (2020-2025)
6.9.4 Jiangsu Hengrui Medicine Co., Ltd Monoclonal Antibodies for Non-small Cell Lung Cancer Product Portfolio
6.9.5 Jiangsu Hengrui Medicine Co., Ltd Recent Developments/Updates
6.10 Innovent Biologics Co., Ltd
6.10.1 Innovent Biologics Co., Ltd Company Information
6.10.2 Innovent Biologics Co., Ltd Description and Business Overview
6.10.3 Innovent Biologics Co., Ltd Monoclonal Antibodies for Non-small Cell Lung Cancer Sales, Revenue and Gross Margin (2020-2025)
6.10.4 Innovent Biologics Co., Ltd Monoclonal Antibodies for Non-small Cell Lung Cancer Product Portfolio
6.10.5 Innovent Biologics Co., Ltd Recent Developments/Updates
6.11 Junshi Biosciences Co., Ltd
6.11.1 Junshi Biosciences Co., Ltd Company Information
6.11.2 Junshi Biosciences Co., Ltd Description and Business Overview
6.11.3 Junshi Biosciences Co., Ltd Monoclonal Antibodies for Non-small Cell Lung Cancer Sales, Revenue and Gross Margin (2020-2025)
6.11.4 Junshi Biosciences Co., Ltd Monoclonal Antibodies for Non-small Cell Lung Cancer Product Portfolio
6.11.5 Junshi Biosciences Co., Ltd Recent Developments/Updates
6.12 BeiGene, Ltd
6.12.1 BeiGene, Ltd Company Information
6.12.2 BeiGene, Ltd Description and Business Overview
6.12.3 BeiGene, Ltd Monoclonal Antibodies for Non-small Cell Lung Cancer Sales, Revenue and Gross Margin (2020-2025)
6.12.4 BeiGene, Ltd Monoclonal Antibodies for Non-small Cell Lung Cancer Product Portfolio
6.12.5 BeiGene, Ltd Recent Developments/Updates
6.13 Akeso, Inc
6.13.1 Akeso, Inc Company Information
6.13.2 Akeso, Inc Description and Business Overview
6.13.3 Akeso, Inc Monoclonal Antibodies for Non-small Cell Lung Cancer Sales, Revenue and Gross Margin (2020-2025)
6.13.4 Akeso, Inc Monoclonal Antibodies for Non-small Cell Lung Cancer Product Portfolio
6.13.5 Akeso, Inc Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Monoclonal Antibodies for Non-small Cell Lung Cancer Industry Chain Analysis
7.2 Monoclonal Antibodies for Non-small Cell Lung Cancer Raw Material Supply Analysis
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Monoclonal Antibodies for Non-small Cell Lung Cancer Production Mode & Process Analysis
7.4 Monoclonal Antibodies for Non-small Cell Lung Cancer Sales and Marketing
7.4.1 Monoclonal Antibodies for Non-small Cell Lung Cancer Sales Channels
7.4.2 Monoclonal Antibodies for Non-small Cell Lung Cancer Distributors
7.5 Monoclonal Antibodies for Non-small Cell Lung Cancer Customer Analysis
8 Monoclonal Antibodies for Non-small Cell Lung Cancer Market Dynamics
8.1 Monoclonal Antibodies for Non-small Cell Lung Cancer Industry Trends
8.2 Monoclonal Antibodies for Non-small Cell Lung Cancer Market Drivers
8.3 Monoclonal Antibodies for Non-small Cell Lung Cancer Market Challenges
8.4 Monoclonal Antibodies for Non-small Cell Lung Cancer Market Restraints
9 Research Findings and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
List of Tables
Table 1. Global Monoclonal Antibodies for Non-small Cell Lung Cancer Market Value Comparison by Type (2024 VS 2031) & (US$ Million)
Table 2. Global Monoclonal Antibodies for Non-small Cell Lung Cancer Market Value by Application (2024 VS 2031) & (US$ Million)
Table 3. Global Monoclonal Antibodies for Non-small Cell Lung Cancer Market Competitive Situation by Manufacturers in 2024
Table 4. Global Monoclonal Antibodies for Non-small Cell Lung Cancer Sales (K Units) of Key Manufacturers (2020-2025)
Table 5. Global Monoclonal Antibodies for Non-small Cell Lung Cancer Sales Market Share by Manufacturers (2020-2025)
Table 6. Global Monoclonal Antibodies for Non-small Cell Lung Cancer Revenue (US$ Million) by Manufacturers (2020-2025)
Table 7. Global Monoclonal Antibodies for Non-small Cell Lung Cancer Revenue Share by Manufacturers (2020-2025)
Table 8. Global Market Monoclonal Antibodies for Non-small Cell Lung Cancer Average Price (US$/Unit) of Key Manufacturers (2020-2025)
Table 9. Global Key Players of Monoclonal Antibodies for Non-small Cell Lung Cancer, Industry Ranking, 2022 VS 2023 VS 2024
Table 10. Global Key Manufacturers of Monoclonal Antibodies for Non-small Cell Lung Cancer, Manufacturing Sites & Headquarters
Table 11. Global Key Manufacturers of Monoclonal Antibodies for Non-small Cell Lung Cancer, Product Type & Application
Table 12. Global Key Manufacturers of Monoclonal Antibodies for Non-small Cell Lung Cancer, Date of Enter into This Industry
Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Global Monoclonal Antibodies for Non-small Cell Lung Cancer by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Monoclonal Antibodies for Non-small Cell Lung Cancer as of 2024)
Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 16. Global Monoclonal Antibodies for Non-small Cell Lung Cancer Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
Table 17. Global Monoclonal Antibodies for Non-small Cell Lung Cancer Sales by Region (2020-2025) & (K Units)
Table 18. Global Monoclonal Antibodies for Non-small Cell Lung Cancer Sales Market Share by Region (2020-2025)
Table 19. Global Monoclonal Antibodies for Non-small Cell Lung Cancer Sales by Region (2026-2031) & (K Units)
Table 20. Global Monoclonal Antibodies for Non-small Cell Lung Cancer Sales Market Share by Region (2026-2031)
Table 21. Global Monoclonal Antibodies for Non-small Cell Lung Cancer Revenue by Region (2020-2025) & (US$ Million)
Table 22. Global Monoclonal Antibodies for Non-small Cell Lung Cancer Revenue Market Share by Region (2020-2025)
Table 23. Global Monoclonal Antibodies for Non-small Cell Lung Cancer Revenue by Region (2026-2031) & (US$ Million)
Table 24. Global Monoclonal Antibodies for Non-small Cell Lung Cancer Revenue Market Share by Region (2026-2031)
Table 25. North America Monoclonal Antibodies for Non-small Cell Lung Cancer Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 26. North America Monoclonal Antibodies for Non-small Cell Lung Cancer Sales by Country (2020-2025) & (K Units)
Table 27. North America Monoclonal Antibodies for Non-small Cell Lung Cancer Sales by Country (2026-2031) & (K Units)
Table 28. North America Monoclonal Antibodies for Non-small Cell Lung Cancer Revenue by Country (2020-2025) & (US$ Million)
Table 29. North America Monoclonal Antibodies for Non-small Cell Lung Cancer Revenue by Country (2026-2031) & (US$ Million)
Table 30. Europe Monoclonal Antibodies for Non-small Cell Lung Cancer Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 31. Europe Monoclonal Antibodies for Non-small Cell Lung Cancer Sales by Country (2020-2025) & (K Units)
Table 32. Europe Monoclonal Antibodies for Non-small Cell Lung Cancer Sales by Country (2026-2031) & (K Units)
Table 33. Europe Monoclonal Antibodies for Non-small Cell Lung Cancer Revenue by Country (2020-2025) & (US$ Million)
Table 34. Europe Monoclonal Antibodies for Non-small Cell Lung Cancer Revenue by Country (2026-2031) & (US$ Million)
Table 35. Asia Pacific Monoclonal Antibodies for Non-small Cell Lung Cancer Revenue by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 36. Asia Pacific Monoclonal Antibodies for Non-small Cell Lung Cancer Sales by Region (2020-2025) & (K Units)
Table 37. Asia Pacific Monoclonal Antibodies for Non-small Cell Lung Cancer Sales by Region (2026-2031) & (K Units)
Table 38. Asia Pacific Monoclonal Antibodies for Non-small Cell Lung Cancer Revenue by Region (2020-2025) & (US$ Million)
Table 39. Asia Pacific Monoclonal Antibodies for Non-small Cell Lung Cancer Revenue by Region (2026-2031) & (US$ Million)
Table 40. Latin America Monoclonal Antibodies for Non-small Cell Lung Cancer Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 41. Latin America Monoclonal Antibodies for Non-small Cell Lung Cancer Sales by Country (2020-2025) & (K Units)
Table 42. Latin America Monoclonal Antibodies for Non-small Cell Lung Cancer Sales by Country (2026-2031) & (K Units)
Table 43. Latin America Monoclonal Antibodies for Non-small Cell Lung Cancer Revenue by Country (2020-2025) & (US$ Million)
Table 44. Latin America Monoclonal Antibodies for Non-small Cell Lung Cancer Revenue by Country (2026-2031) & (US$ Million)
Table 45. Middle East and Africa Monoclonal Antibodies for Non-small Cell Lung Cancer Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 46. Middle East and Africa Monoclonal Antibodies for Non-small Cell Lung Cancer Sales by Country (2020-2025) & (K Units)
Table 47. Middle East and Africa Monoclonal Antibodies for Non-small Cell Lung Cancer Sales by Country (2026-2031) & (K Units)
Table 48. Middle East and Africa Monoclonal Antibodies for Non-small Cell Lung Cancer Revenue by Country (2020-2025) & (US$ Million)
Table 49. Middle East and Africa Monoclonal Antibodies for Non-small Cell Lung Cancer Revenue by Country (2026-2031) & (US$ Million)
Table 50. Global Monoclonal Antibodies for Non-small Cell Lung Cancer Sales (K Units) by Type (2020-2025)
Table 51. Global Monoclonal Antibodies for Non-small Cell Lung Cancer Sales (K Units) by Type (2026-2031)
Table 52. Global Monoclonal Antibodies for Non-small Cell Lung Cancer Sales Market Share by Type (2020-2025)
Table 53. Global Monoclonal Antibodies for Non-small Cell Lung Cancer Sales Market Share by Type (2026-2031)
Table 54. Global Monoclonal Antibodies for Non-small Cell Lung Cancer Revenue (US$ Million) by Type (2020-2025)
Table 55. Global Monoclonal Antibodies for Non-small Cell Lung Cancer Revenue (US$ Million) by Type (2026-2031)
Table 56. Global Monoclonal Antibodies for Non-small Cell Lung Cancer Revenue Market Share by Type (2020-2025)
Table 57. Global Monoclonal Antibodies for Non-small Cell Lung Cancer Revenue Market Share by Type (2026-2031)
Table 58. Global Monoclonal Antibodies for Non-small Cell Lung Cancer Price (US$/Unit) by Type (2020-2025)
Table 59. Global Monoclonal Antibodies for Non-small Cell Lung Cancer Price (US$/Unit) by Type (2026-2031)
Table 60. Global Monoclonal Antibodies for Non-small Cell Lung Cancer Sales (K Units) by Application (2020-2025)
Table 61. Global Monoclonal Antibodies for Non-small Cell Lung Cancer Sales (K Units) by Application (2026-2031)
Table 62. Global Monoclonal Antibodies for Non-small Cell Lung Cancer Sales Market Share by Application (2020-2025)
Table 63. Global Monoclonal Antibodies for Non-small Cell Lung Cancer Sales Market Share by Application (2026-2031)
Table 64. Global Monoclonal Antibodies for Non-small Cell Lung Cancer Revenue (US$ Million) by Application (2020-2025)
Table 65. Global Monoclonal Antibodies for Non-small Cell Lung Cancer Revenue (US$ Million) by Application (2026-2031)
Table 66. Global Monoclonal Antibodies for Non-small Cell Lung Cancer Revenue Market Share by Application (2020-2025)
Table 67. Global Monoclonal Antibodies for Non-small Cell Lung Cancer Revenue Market Share by Application (2026-2031)
Table 68. Global Monoclonal Antibodies for Non-small Cell Lung Cancer Price (US$/Unit) by Application (2020-2025)
Table 69. Global Monoclonal Antibodies for Non-small Cell Lung Cancer Price (US$/Unit) by Application (2026-2031)
Table 70. Roche Holding AG Company Information
Table 71. Roche Holding AG Description and Business Overview
Table 72. Roche Holding AG Monoclonal Antibodies for Non-small Cell Lung Cancer Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 73. Roche Holding AG Monoclonal Antibodies for Non-small Cell Lung Cancer Product
Table 74. Roche Holding AG Recent Developments/Updates
Table 75. Bristol Myers Squibb Co. Company Information
Table 76. Bristol Myers Squibb Co. Description and Business Overview
Table 77. Bristol Myers Squibb Co. Monoclonal Antibodies for Non-small Cell Lung Cancer Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 78. Bristol Myers Squibb Co. Monoclonal Antibodies for Non-small Cell Lung Cancer Product
Table 79. Bristol Myers Squibb Co. Recent Developments/Updates
Table 80. Elea Spa Company Information
Table 81. Elea Spa Description and Business Overview
Table 82. Elea Spa Monoclonal Antibodies for Non-small Cell Lung Cancer Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 83. Elea Spa Monoclonal Antibodies for Non-small Cell Lung Cancer Product
Table 84. Elea Spa Recent Developments/Updates
Table 85. Eli Lilly & Co. Company Information
Table 86. Eli Lilly & Co. Description and Business Overview
Table 87. Eli Lilly & Co. Monoclonal Antibodies for Non-small Cell Lung Cancer Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 88. Eli Lilly & Co. Monoclonal Antibodies for Non-small Cell Lung Cancer Product
Table 89. Eli Lilly & Co. Recent Developments/Updates
Table 90. Merck & Co., Inc. Company Information
Table 91. Merck & Co., Inc. Description and Business Overview
Table 92. Merck & Co., Inc. Monoclonal Antibodies for Non-small Cell Lung Cancer Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 93. Merck & Co., Inc. Monoclonal Antibodies for Non-small Cell Lung Cancer Product
Table 94. Merck & Co., Inc. Recent Developments/Updates
Table 95. AstraZeneca PLC Company Information
Table 96. AstraZeneca PLC Description and Business Overview
Table 97. AstraZeneca PLC Monoclonal Antibodies for Non-small Cell Lung Cancer Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 98. AstraZeneca PLC Monoclonal Antibodies for Non-small Cell Lung Cancer Product
Table 99. AstraZeneca PLC Recent Developments/Updates
Table 100. Regeneron Pharmaceuticals, Inc. Company Information
Table 101. Regeneron Pharmaceuticals, Inc. Description and Business Overview
Table 102. Regeneron Pharmaceuticals, Inc. Monoclonal Antibodies for Non-small Cell Lung Cancer Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 103. Regeneron Pharmaceuticals, Inc. Monoclonal Antibodies for Non-small Cell Lung Cancer Product
Table 104. Regeneron Pharmaceuticals, Inc. Recent Developments/Updates
Table 105. Henlius Biopharma Co., Ltd Company Information
Table 106. Henlius Biopharma Co., Ltd Description and Business Overview
Table 107. Henlius Biopharma Co., Ltd Monoclonal Antibodies for Non-small Cell Lung Cancer Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 108. Henlius Biopharma Co., Ltd Monoclonal Antibodies for Non-small Cell Lung Cancer Product
Table 109. Henlius Biopharma Co., Ltd Recent Developments/Updates
Table 110. Jiangsu Hengrui Medicine Co., Ltd Company Information
Table 111. Jiangsu Hengrui Medicine Co., Ltd Description and Business Overview
Table 112. Jiangsu Hengrui Medicine Co., Ltd Monoclonal Antibodies for Non-small Cell Lung Cancer Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 113. Jiangsu Hengrui Medicine Co., Ltd Monoclonal Antibodies for Non-small Cell Lung Cancer Product
Table 114. Jiangsu Hengrui Medicine Co., Ltd Recent Developments/Updates
Table 115. Innovent Biologics Co., Ltd Company Information
Table 116. Innovent Biologics Co., Ltd Description and Business Overview
Table 117. Innovent Biologics Co., Ltd Monoclonal Antibodies for Non-small Cell Lung Cancer Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 118. Innovent Biologics Co., Ltd Monoclonal Antibodies for Non-small Cell Lung Cancer Product
Table 119. Innovent Biologics Co., Ltd Recent Developments/Updates
Table 120. Junshi Biosciences Co., Ltd Company Information
Table 121. Junshi Biosciences Co., Ltd Description and Business Overview
Table 122. Junshi Biosciences Co., Ltd Monoclonal Antibodies for Non-small Cell Lung Cancer Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 123. Junshi Biosciences Co., Ltd Monoclonal Antibodies for Non-small Cell Lung Cancer Product
Table 124. Junshi Biosciences Co., Ltd Recent Developments/Updates
Table 125. BeiGene, Ltd Company Information
Table 126. BeiGene, Ltd Description and Business Overview
Table 127. BeiGene, Ltd Monoclonal Antibodies for Non-small Cell Lung Cancer Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 128. BeiGene, Ltd Monoclonal Antibodies for Non-small Cell Lung Cancer Product
Table 129. BeiGene, Ltd Recent Developments/Updates
Table 130. Akeso, Inc Company Information
Table 131. Akeso, Inc Description and Business Overview
Table 132. Akeso, Inc Monoclonal Antibodies for Non-small Cell Lung Cancer Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 133. Akeso, Inc Monoclonal Antibodies for Non-small Cell Lung Cancer Product
Table 134. Akeso, Inc Recent Developments/Updates
Table 135. Key Raw Materials Lists
Table 136. Raw Materials Key Suppliers Lists
Table 137. Monoclonal Antibodies for Non-small Cell Lung Cancer Distributors List
Table 138. Monoclonal Antibodies for Non-small Cell Lung Cancer Customers List
Table 139. Monoclonal Antibodies for Non-small Cell Lung Cancer Market Trends
Table 140. Monoclonal Antibodies for Non-small Cell Lung Cancer Market Drivers
Table 141. Monoclonal Antibodies for Non-small Cell Lung Cancer Market Challenges
Table 142. Monoclonal Antibodies for Non-small Cell Lung Cancer Market Restraints
Table 143. Research Programs/Design for This Report
Table 144. Key Data Information from Secondary Sources
Table 145. Key Data Information from Primary Sources
Table 146. Authors List of This Report
List of Figures
Figure 1. Product Picture of Monoclonal Antibodies for Non-small Cell Lung Cancer
Figure 2. Global Monoclonal Antibodies for Non-small Cell Lung Cancer Market Value Comparison by Type (2020-2031) & (US$ Million)
Figure 3. Global Monoclonal Antibodies for Non-small Cell Lung Cancer Market Share by Type: 2024 & 2031
Figure 4. 5 mg/mL Product Picture
Figure 5. 10 mg/mL Product Picture
Figure 6. 25 mg/mL Product Picture
Figure 7. 50 mg/mL Product Picture
Figure 8. Global Monoclonal Antibodies for Non-small Cell Lung Cancer Market Value by Application (2020-2031) & (US$ Million)
Figure 9. Global Monoclonal Antibodies for Non-small Cell Lung Cancer Market Share by Application: 2024 & 2031
Figure 10. Hospitals
Figure 11. Clinic
Figure 12. Others
Figure 13. Global Monoclonal Antibodies for Non-small Cell Lung Cancer Revenue, (US$ Million), 2020 VS 2024 VS 2031
Figure 14. Global Monoclonal Antibodies for Non-small Cell Lung Cancer Market Size (2020-2031) & (US$ Million)
Figure 15. Global Monoclonal Antibodies for Non-small Cell Lung Cancer Sales (2020-2031) & (K Units)
Figure 16. Global Monoclonal Antibodies for Non-small Cell Lung Cancer Average Price (US$/Unit) & (2020-2031)
Figure 17. Monoclonal Antibodies for Non-small Cell Lung Cancer Report Years Considered
Figure 18. Monoclonal Antibodies for Non-small Cell Lung Cancer Sales Share by Manufacturers in 2024
Figure 19. Global Monoclonal Antibodies for Non-small Cell Lung Cancer Revenue Share by Manufacturers in 2024
Figure 20. Global 5 and 10 Largest Monoclonal Antibodies for Non-small Cell Lung Cancer Players: Market Share by Revenue in Monoclonal Antibodies for Non-small Cell Lung Cancer in 2024
Figure 21. Monoclonal Antibodies for Non-small Cell Lung Cancer Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2020 VS 2024
Figure 22. Global Monoclonal Antibodies for Non-small Cell Lung Cancer Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
Figure 23. North America Monoclonal Antibodies for Non-small Cell Lung Cancer Sales Market Share by Country (2020-2031)
Figure 24. North America Monoclonal Antibodies for Non-small Cell Lung Cancer Revenue Market Share by Country (2020-2031)
Figure 25. United States Monoclonal Antibodies for Non-small Cell Lung Cancer Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 26. Canada Monoclonal Antibodies for Non-small Cell Lung Cancer Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 27. Europe Monoclonal Antibodies for Non-small Cell Lung Cancer Sales Market Share by Country (2020-2031)
Figure 28. Europe Monoclonal Antibodies for Non-small Cell Lung Cancer Revenue Market Share by Country (2020-2031)
Figure 29. Germany Monoclonal Antibodies for Non-small Cell Lung Cancer Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 30. France Monoclonal Antibodies for Non-small Cell Lung Cancer Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 31. U.K. Monoclonal Antibodies for Non-small Cell Lung Cancer Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 32. Italy Monoclonal Antibodies for Non-small Cell Lung Cancer Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 33. Russia Monoclonal Antibodies for Non-small Cell Lung Cancer Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 34. Asia Pacific Monoclonal Antibodies for Non-small Cell Lung Cancer Sales Market Share by Region (2020-2031)
Figure 35. Asia Pacific Monoclonal Antibodies for Non-small Cell Lung Cancer Revenue Market Share by Region (2020-2031)
Figure 36. China Monoclonal Antibodies for Non-small Cell Lung Cancer Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 37. Japan Monoclonal Antibodies for Non-small Cell Lung Cancer Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 38. South Korea Monoclonal Antibodies for Non-small Cell Lung Cancer Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 39. India Monoclonal Antibodies for Non-small Cell Lung Cancer Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 40. Australia Monoclonal Antibodies for Non-small Cell Lung Cancer Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 41. China Taiwan Monoclonal Antibodies for Non-small Cell Lung Cancer Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 42. Southeast Asia Monoclonal Antibodies for Non-small Cell Lung Cancer Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 43. Latin America Monoclonal Antibodies for Non-small Cell Lung Cancer Sales Market Share by Country (2020-2031)
Figure 44. Latin America Monoclonal Antibodies for Non-small Cell Lung Cancer Revenue Market Share by Country (2020-2031)
Figure 45. Mexico Monoclonal Antibodies for Non-small Cell Lung Cancer Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 46. Brazil Monoclonal Antibodies for Non-small Cell Lung Cancer Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 47. Argentina Monoclonal Antibodies for Non-small Cell Lung Cancer Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 48. Colombia Monoclonal Antibodies for Non-small Cell Lung Cancer Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 49. Middle East and Africa Monoclonal Antibodies for Non-small Cell Lung Cancer Sales Market Share by Country (2020-2031)
Figure 50. Middle East and Africa Monoclonal Antibodies for Non-small Cell Lung Cancer Revenue Market Share by Country (2020-2031)
Figure 51. Turkey Monoclonal Antibodies for Non-small Cell Lung Cancer Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 52. Saudi Arabia Monoclonal Antibodies for Non-small Cell Lung Cancer Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 53. UAE Monoclonal Antibodies for Non-small Cell Lung Cancer Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 54. Global Sales Market Share of Monoclonal Antibodies for Non-small Cell Lung Cancer by Type (2020-2031)
Figure 55. Global Revenue Market Share of Monoclonal Antibodies for Non-small Cell Lung Cancer by Type (2020-2031)
Figure 56. Global Monoclonal Antibodies for Non-small Cell Lung Cancer Price (US$/Unit) by Type (2020-2031)
Figure 57. Global Sales Market Share of Monoclonal Antibodies for Non-small Cell Lung Cancer by Application (2020-2031)
Figure 58. Global Revenue Market Share of Monoclonal Antibodies for Non-small Cell Lung Cancer by Application (2020-2031)
Figure 59. Global Monoclonal Antibodies for Non-small Cell Lung Cancer Price (US$/Unit) by Application (2020-2031)
Figure 60. Monoclonal Antibodies for Non-small Cell Lung Cancer Value Chain
Figure 61. Channels of Distribution (Direct Vs Distribution)
Figure 62. Bottom-up and Top-down Approaches for This Report
Figure 63. Data Triangulation
Figure 64. Key Executives Interviewed
Table 1. Global Monoclonal Antibodies for Non-small Cell Lung Cancer Market Value Comparison by Type (2024 VS 2031) & (US$ Million)
Table 2. Global Monoclonal Antibodies for Non-small Cell Lung Cancer Market Value by Application (2024 VS 2031) & (US$ Million)
Table 3. Global Monoclonal Antibodies for Non-small Cell Lung Cancer Market Competitive Situation by Manufacturers in 2024
Table 4. Global Monoclonal Antibodies for Non-small Cell Lung Cancer Sales (K Units) of Key Manufacturers (2020-2025)
Table 5. Global Monoclonal Antibodies for Non-small Cell Lung Cancer Sales Market Share by Manufacturers (2020-2025)
Table 6. Global Monoclonal Antibodies for Non-small Cell Lung Cancer Revenue (US$ Million) by Manufacturers (2020-2025)
Table 7. Global Monoclonal Antibodies for Non-small Cell Lung Cancer Revenue Share by Manufacturers (2020-2025)
Table 8. Global Market Monoclonal Antibodies for Non-small Cell Lung Cancer Average Price (US$/Unit) of Key Manufacturers (2020-2025)
Table 9. Global Key Players of Monoclonal Antibodies for Non-small Cell Lung Cancer, Industry Ranking, 2022 VS 2023 VS 2024
Table 10. Global Key Manufacturers of Monoclonal Antibodies for Non-small Cell Lung Cancer, Manufacturing Sites & Headquarters
Table 11. Global Key Manufacturers of Monoclonal Antibodies for Non-small Cell Lung Cancer, Product Type & Application
Table 12. Global Key Manufacturers of Monoclonal Antibodies for Non-small Cell Lung Cancer, Date of Enter into This Industry
Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Global Monoclonal Antibodies for Non-small Cell Lung Cancer by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Monoclonal Antibodies for Non-small Cell Lung Cancer as of 2024)
Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 16. Global Monoclonal Antibodies for Non-small Cell Lung Cancer Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
Table 17. Global Monoclonal Antibodies for Non-small Cell Lung Cancer Sales by Region (2020-2025) & (K Units)
Table 18. Global Monoclonal Antibodies for Non-small Cell Lung Cancer Sales Market Share by Region (2020-2025)
Table 19. Global Monoclonal Antibodies for Non-small Cell Lung Cancer Sales by Region (2026-2031) & (K Units)
Table 20. Global Monoclonal Antibodies for Non-small Cell Lung Cancer Sales Market Share by Region (2026-2031)
Table 21. Global Monoclonal Antibodies for Non-small Cell Lung Cancer Revenue by Region (2020-2025) & (US$ Million)
Table 22. Global Monoclonal Antibodies for Non-small Cell Lung Cancer Revenue Market Share by Region (2020-2025)
Table 23. Global Monoclonal Antibodies for Non-small Cell Lung Cancer Revenue by Region (2026-2031) & (US$ Million)
Table 24. Global Monoclonal Antibodies for Non-small Cell Lung Cancer Revenue Market Share by Region (2026-2031)
Table 25. North America Monoclonal Antibodies for Non-small Cell Lung Cancer Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 26. North America Monoclonal Antibodies for Non-small Cell Lung Cancer Sales by Country (2020-2025) & (K Units)
Table 27. North America Monoclonal Antibodies for Non-small Cell Lung Cancer Sales by Country (2026-2031) & (K Units)
Table 28. North America Monoclonal Antibodies for Non-small Cell Lung Cancer Revenue by Country (2020-2025) & (US$ Million)
Table 29. North America Monoclonal Antibodies for Non-small Cell Lung Cancer Revenue by Country (2026-2031) & (US$ Million)
Table 30. Europe Monoclonal Antibodies for Non-small Cell Lung Cancer Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 31. Europe Monoclonal Antibodies for Non-small Cell Lung Cancer Sales by Country (2020-2025) & (K Units)
Table 32. Europe Monoclonal Antibodies for Non-small Cell Lung Cancer Sales by Country (2026-2031) & (K Units)
Table 33. Europe Monoclonal Antibodies for Non-small Cell Lung Cancer Revenue by Country (2020-2025) & (US$ Million)
Table 34. Europe Monoclonal Antibodies for Non-small Cell Lung Cancer Revenue by Country (2026-2031) & (US$ Million)
Table 35. Asia Pacific Monoclonal Antibodies for Non-small Cell Lung Cancer Revenue by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 36. Asia Pacific Monoclonal Antibodies for Non-small Cell Lung Cancer Sales by Region (2020-2025) & (K Units)
Table 37. Asia Pacific Monoclonal Antibodies for Non-small Cell Lung Cancer Sales by Region (2026-2031) & (K Units)
Table 38. Asia Pacific Monoclonal Antibodies for Non-small Cell Lung Cancer Revenue by Region (2020-2025) & (US$ Million)
Table 39. Asia Pacific Monoclonal Antibodies for Non-small Cell Lung Cancer Revenue by Region (2026-2031) & (US$ Million)
Table 40. Latin America Monoclonal Antibodies for Non-small Cell Lung Cancer Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 41. Latin America Monoclonal Antibodies for Non-small Cell Lung Cancer Sales by Country (2020-2025) & (K Units)
Table 42. Latin America Monoclonal Antibodies for Non-small Cell Lung Cancer Sales by Country (2026-2031) & (K Units)
Table 43. Latin America Monoclonal Antibodies for Non-small Cell Lung Cancer Revenue by Country (2020-2025) & (US$ Million)
Table 44. Latin America Monoclonal Antibodies for Non-small Cell Lung Cancer Revenue by Country (2026-2031) & (US$ Million)
Table 45. Middle East and Africa Monoclonal Antibodies for Non-small Cell Lung Cancer Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 46. Middle East and Africa Monoclonal Antibodies for Non-small Cell Lung Cancer Sales by Country (2020-2025) & (K Units)
Table 47. Middle East and Africa Monoclonal Antibodies for Non-small Cell Lung Cancer Sales by Country (2026-2031) & (K Units)
Table 48. Middle East and Africa Monoclonal Antibodies for Non-small Cell Lung Cancer Revenue by Country (2020-2025) & (US$ Million)
Table 49. Middle East and Africa Monoclonal Antibodies for Non-small Cell Lung Cancer Revenue by Country (2026-2031) & (US$ Million)
Table 50. Global Monoclonal Antibodies for Non-small Cell Lung Cancer Sales (K Units) by Type (2020-2025)
Table 51. Global Monoclonal Antibodies for Non-small Cell Lung Cancer Sales (K Units) by Type (2026-2031)
Table 52. Global Monoclonal Antibodies for Non-small Cell Lung Cancer Sales Market Share by Type (2020-2025)
Table 53. Global Monoclonal Antibodies for Non-small Cell Lung Cancer Sales Market Share by Type (2026-2031)
Table 54. Global Monoclonal Antibodies for Non-small Cell Lung Cancer Revenue (US$ Million) by Type (2020-2025)
Table 55. Global Monoclonal Antibodies for Non-small Cell Lung Cancer Revenue (US$ Million) by Type (2026-2031)
Table 56. Global Monoclonal Antibodies for Non-small Cell Lung Cancer Revenue Market Share by Type (2020-2025)
Table 57. Global Monoclonal Antibodies for Non-small Cell Lung Cancer Revenue Market Share by Type (2026-2031)
Table 58. Global Monoclonal Antibodies for Non-small Cell Lung Cancer Price (US$/Unit) by Type (2020-2025)
Table 59. Global Monoclonal Antibodies for Non-small Cell Lung Cancer Price (US$/Unit) by Type (2026-2031)
Table 60. Global Monoclonal Antibodies for Non-small Cell Lung Cancer Sales (K Units) by Application (2020-2025)
Table 61. Global Monoclonal Antibodies for Non-small Cell Lung Cancer Sales (K Units) by Application (2026-2031)
Table 62. Global Monoclonal Antibodies for Non-small Cell Lung Cancer Sales Market Share by Application (2020-2025)
Table 63. Global Monoclonal Antibodies for Non-small Cell Lung Cancer Sales Market Share by Application (2026-2031)
Table 64. Global Monoclonal Antibodies for Non-small Cell Lung Cancer Revenue (US$ Million) by Application (2020-2025)
Table 65. Global Monoclonal Antibodies for Non-small Cell Lung Cancer Revenue (US$ Million) by Application (2026-2031)
Table 66. Global Monoclonal Antibodies for Non-small Cell Lung Cancer Revenue Market Share by Application (2020-2025)
Table 67. Global Monoclonal Antibodies for Non-small Cell Lung Cancer Revenue Market Share by Application (2026-2031)
Table 68. Global Monoclonal Antibodies for Non-small Cell Lung Cancer Price (US$/Unit) by Application (2020-2025)
Table 69. Global Monoclonal Antibodies for Non-small Cell Lung Cancer Price (US$/Unit) by Application (2026-2031)
Table 70. Roche Holding AG Company Information
Table 71. Roche Holding AG Description and Business Overview
Table 72. Roche Holding AG Monoclonal Antibodies for Non-small Cell Lung Cancer Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 73. Roche Holding AG Monoclonal Antibodies for Non-small Cell Lung Cancer Product
Table 74. Roche Holding AG Recent Developments/Updates
Table 75. Bristol Myers Squibb Co. Company Information
Table 76. Bristol Myers Squibb Co. Description and Business Overview
Table 77. Bristol Myers Squibb Co. Monoclonal Antibodies for Non-small Cell Lung Cancer Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 78. Bristol Myers Squibb Co. Monoclonal Antibodies for Non-small Cell Lung Cancer Product
Table 79. Bristol Myers Squibb Co. Recent Developments/Updates
Table 80. Elea Spa Company Information
Table 81. Elea Spa Description and Business Overview
Table 82. Elea Spa Monoclonal Antibodies for Non-small Cell Lung Cancer Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 83. Elea Spa Monoclonal Antibodies for Non-small Cell Lung Cancer Product
Table 84. Elea Spa Recent Developments/Updates
Table 85. Eli Lilly & Co. Company Information
Table 86. Eli Lilly & Co. Description and Business Overview
Table 87. Eli Lilly & Co. Monoclonal Antibodies for Non-small Cell Lung Cancer Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 88. Eli Lilly & Co. Monoclonal Antibodies for Non-small Cell Lung Cancer Product
Table 89. Eli Lilly & Co. Recent Developments/Updates
Table 90. Merck & Co., Inc. Company Information
Table 91. Merck & Co., Inc. Description and Business Overview
Table 92. Merck & Co., Inc. Monoclonal Antibodies for Non-small Cell Lung Cancer Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 93. Merck & Co., Inc. Monoclonal Antibodies for Non-small Cell Lung Cancer Product
Table 94. Merck & Co., Inc. Recent Developments/Updates
Table 95. AstraZeneca PLC Company Information
Table 96. AstraZeneca PLC Description and Business Overview
Table 97. AstraZeneca PLC Monoclonal Antibodies for Non-small Cell Lung Cancer Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 98. AstraZeneca PLC Monoclonal Antibodies for Non-small Cell Lung Cancer Product
Table 99. AstraZeneca PLC Recent Developments/Updates
Table 100. Regeneron Pharmaceuticals, Inc. Company Information
Table 101. Regeneron Pharmaceuticals, Inc. Description and Business Overview
Table 102. Regeneron Pharmaceuticals, Inc. Monoclonal Antibodies for Non-small Cell Lung Cancer Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 103. Regeneron Pharmaceuticals, Inc. Monoclonal Antibodies for Non-small Cell Lung Cancer Product
Table 104. Regeneron Pharmaceuticals, Inc. Recent Developments/Updates
Table 105. Henlius Biopharma Co., Ltd Company Information
Table 106. Henlius Biopharma Co., Ltd Description and Business Overview
Table 107. Henlius Biopharma Co., Ltd Monoclonal Antibodies for Non-small Cell Lung Cancer Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 108. Henlius Biopharma Co., Ltd Monoclonal Antibodies for Non-small Cell Lung Cancer Product
Table 109. Henlius Biopharma Co., Ltd Recent Developments/Updates
Table 110. Jiangsu Hengrui Medicine Co., Ltd Company Information
Table 111. Jiangsu Hengrui Medicine Co., Ltd Description and Business Overview
Table 112. Jiangsu Hengrui Medicine Co., Ltd Monoclonal Antibodies for Non-small Cell Lung Cancer Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 113. Jiangsu Hengrui Medicine Co., Ltd Monoclonal Antibodies for Non-small Cell Lung Cancer Product
Table 114. Jiangsu Hengrui Medicine Co., Ltd Recent Developments/Updates
Table 115. Innovent Biologics Co., Ltd Company Information
Table 116. Innovent Biologics Co., Ltd Description and Business Overview
Table 117. Innovent Biologics Co., Ltd Monoclonal Antibodies for Non-small Cell Lung Cancer Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 118. Innovent Biologics Co., Ltd Monoclonal Antibodies for Non-small Cell Lung Cancer Product
Table 119. Innovent Biologics Co., Ltd Recent Developments/Updates
Table 120. Junshi Biosciences Co., Ltd Company Information
Table 121. Junshi Biosciences Co., Ltd Description and Business Overview
Table 122. Junshi Biosciences Co., Ltd Monoclonal Antibodies for Non-small Cell Lung Cancer Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 123. Junshi Biosciences Co., Ltd Monoclonal Antibodies for Non-small Cell Lung Cancer Product
Table 124. Junshi Biosciences Co., Ltd Recent Developments/Updates
Table 125. BeiGene, Ltd Company Information
Table 126. BeiGene, Ltd Description and Business Overview
Table 127. BeiGene, Ltd Monoclonal Antibodies for Non-small Cell Lung Cancer Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 128. BeiGene, Ltd Monoclonal Antibodies for Non-small Cell Lung Cancer Product
Table 129. BeiGene, Ltd Recent Developments/Updates
Table 130. Akeso, Inc Company Information
Table 131. Akeso, Inc Description and Business Overview
Table 132. Akeso, Inc Monoclonal Antibodies for Non-small Cell Lung Cancer Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 133. Akeso, Inc Monoclonal Antibodies for Non-small Cell Lung Cancer Product
Table 134. Akeso, Inc Recent Developments/Updates
Table 135. Key Raw Materials Lists
Table 136. Raw Materials Key Suppliers Lists
Table 137. Monoclonal Antibodies for Non-small Cell Lung Cancer Distributors List
Table 138. Monoclonal Antibodies for Non-small Cell Lung Cancer Customers List
Table 139. Monoclonal Antibodies for Non-small Cell Lung Cancer Market Trends
Table 140. Monoclonal Antibodies for Non-small Cell Lung Cancer Market Drivers
Table 141. Monoclonal Antibodies for Non-small Cell Lung Cancer Market Challenges
Table 142. Monoclonal Antibodies for Non-small Cell Lung Cancer Market Restraints
Table 143. Research Programs/Design for This Report
Table 144. Key Data Information from Secondary Sources
Table 145. Key Data Information from Primary Sources
Table 146. Authors List of This Report
List of Figures
Figure 1. Product Picture of Monoclonal Antibodies for Non-small Cell Lung Cancer
Figure 2. Global Monoclonal Antibodies for Non-small Cell Lung Cancer Market Value Comparison by Type (2020-2031) & (US$ Million)
Figure 3. Global Monoclonal Antibodies for Non-small Cell Lung Cancer Market Share by Type: 2024 & 2031
Figure 4. 5 mg/mL Product Picture
Figure 5. 10 mg/mL Product Picture
Figure 6. 25 mg/mL Product Picture
Figure 7. 50 mg/mL Product Picture
Figure 8. Global Monoclonal Antibodies for Non-small Cell Lung Cancer Market Value by Application (2020-2031) & (US$ Million)
Figure 9. Global Monoclonal Antibodies for Non-small Cell Lung Cancer Market Share by Application: 2024 & 2031
Figure 10. Hospitals
Figure 11. Clinic
Figure 12. Others
Figure 13. Global Monoclonal Antibodies for Non-small Cell Lung Cancer Revenue, (US$ Million), 2020 VS 2024 VS 2031
Figure 14. Global Monoclonal Antibodies for Non-small Cell Lung Cancer Market Size (2020-2031) & (US$ Million)
Figure 15. Global Monoclonal Antibodies for Non-small Cell Lung Cancer Sales (2020-2031) & (K Units)
Figure 16. Global Monoclonal Antibodies for Non-small Cell Lung Cancer Average Price (US$/Unit) & (2020-2031)
Figure 17. Monoclonal Antibodies for Non-small Cell Lung Cancer Report Years Considered
Figure 18. Monoclonal Antibodies for Non-small Cell Lung Cancer Sales Share by Manufacturers in 2024
Figure 19. Global Monoclonal Antibodies for Non-small Cell Lung Cancer Revenue Share by Manufacturers in 2024
Figure 20. Global 5 and 10 Largest Monoclonal Antibodies for Non-small Cell Lung Cancer Players: Market Share by Revenue in Monoclonal Antibodies for Non-small Cell Lung Cancer in 2024
Figure 21. Monoclonal Antibodies for Non-small Cell Lung Cancer Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2020 VS 2024
Figure 22. Global Monoclonal Antibodies for Non-small Cell Lung Cancer Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
Figure 23. North America Monoclonal Antibodies for Non-small Cell Lung Cancer Sales Market Share by Country (2020-2031)
Figure 24. North America Monoclonal Antibodies for Non-small Cell Lung Cancer Revenue Market Share by Country (2020-2031)
Figure 25. United States Monoclonal Antibodies for Non-small Cell Lung Cancer Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 26. Canada Monoclonal Antibodies for Non-small Cell Lung Cancer Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 27. Europe Monoclonal Antibodies for Non-small Cell Lung Cancer Sales Market Share by Country (2020-2031)
Figure 28. Europe Monoclonal Antibodies for Non-small Cell Lung Cancer Revenue Market Share by Country (2020-2031)
Figure 29. Germany Monoclonal Antibodies for Non-small Cell Lung Cancer Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 30. France Monoclonal Antibodies for Non-small Cell Lung Cancer Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 31. U.K. Monoclonal Antibodies for Non-small Cell Lung Cancer Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 32. Italy Monoclonal Antibodies for Non-small Cell Lung Cancer Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 33. Russia Monoclonal Antibodies for Non-small Cell Lung Cancer Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 34. Asia Pacific Monoclonal Antibodies for Non-small Cell Lung Cancer Sales Market Share by Region (2020-2031)
Figure 35. Asia Pacific Monoclonal Antibodies for Non-small Cell Lung Cancer Revenue Market Share by Region (2020-2031)
Figure 36. China Monoclonal Antibodies for Non-small Cell Lung Cancer Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 37. Japan Monoclonal Antibodies for Non-small Cell Lung Cancer Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 38. South Korea Monoclonal Antibodies for Non-small Cell Lung Cancer Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 39. India Monoclonal Antibodies for Non-small Cell Lung Cancer Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 40. Australia Monoclonal Antibodies for Non-small Cell Lung Cancer Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 41. China Taiwan Monoclonal Antibodies for Non-small Cell Lung Cancer Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 42. Southeast Asia Monoclonal Antibodies for Non-small Cell Lung Cancer Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 43. Latin America Monoclonal Antibodies for Non-small Cell Lung Cancer Sales Market Share by Country (2020-2031)
Figure 44. Latin America Monoclonal Antibodies for Non-small Cell Lung Cancer Revenue Market Share by Country (2020-2031)
Figure 45. Mexico Monoclonal Antibodies for Non-small Cell Lung Cancer Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 46. Brazil Monoclonal Antibodies for Non-small Cell Lung Cancer Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 47. Argentina Monoclonal Antibodies for Non-small Cell Lung Cancer Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 48. Colombia Monoclonal Antibodies for Non-small Cell Lung Cancer Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 49. Middle East and Africa Monoclonal Antibodies for Non-small Cell Lung Cancer Sales Market Share by Country (2020-2031)
Figure 50. Middle East and Africa Monoclonal Antibodies for Non-small Cell Lung Cancer Revenue Market Share by Country (2020-2031)
Figure 51. Turkey Monoclonal Antibodies for Non-small Cell Lung Cancer Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 52. Saudi Arabia Monoclonal Antibodies for Non-small Cell Lung Cancer Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 53. UAE Monoclonal Antibodies for Non-small Cell Lung Cancer Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 54. Global Sales Market Share of Monoclonal Antibodies for Non-small Cell Lung Cancer by Type (2020-2031)
Figure 55. Global Revenue Market Share of Monoclonal Antibodies for Non-small Cell Lung Cancer by Type (2020-2031)
Figure 56. Global Monoclonal Antibodies for Non-small Cell Lung Cancer Price (US$/Unit) by Type (2020-2031)
Figure 57. Global Sales Market Share of Monoclonal Antibodies for Non-small Cell Lung Cancer by Application (2020-2031)
Figure 58. Global Revenue Market Share of Monoclonal Antibodies for Non-small Cell Lung Cancer by Application (2020-2031)
Figure 59. Global Monoclonal Antibodies for Non-small Cell Lung Cancer Price (US$/Unit) by Application (2020-2031)
Figure 60. Monoclonal Antibodies for Non-small Cell Lung Cancer Value Chain
Figure 61. Channels of Distribution (Direct Vs Distribution)
Figure 62. Bottom-up and Top-down Approaches for This Report
Figure 63. Data Triangulation
Figure 64. Key Executives Interviewed
Our team would be happy to assist you with your queries.
About us
Accurate data, The latest market trends, And deeper research directions.
Our sole purpose is to provide a basis for leaders in all walks of life to make more appropriate decisions, to help companies solve existing problems and achieve business goals
Latest reports
Global Ethylene Oxide (EO) Market Research Report 2026
Jan 17, 26
Global Stem Cells Cryopreservation Equipments Market Research Report 2026
Jan 17, 26
Global Selenium-enriched Yeast Market Research Report 2026
Jan 17, 26
Useful links
Our Contacts
Room 2306, T6 Fuxing World Financial Center, Kaifu District, Changsha, Hunan, China
(+86) 159 1069 5232